Mannatech Announces Promotion Of Landen Fredrick To President And CEO

3/14/24 2:59:59 AM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $MTEX alert in real time by email

Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech.

Mr. Fredrick further stated, "Coinciding with Al's retirement, I am pleased to announce the promotion of Landen Fredrick to the position of President and CEO. Landen's succession to the CEO position was made possible by Al's mentorship over the past few years where Landen served as President and Chief Operating Officer. As CEO, Landen will oversee the senior executive team and the team of general managers over our international markets, driving operational excellence, and executing the company's strategic initiatives."

Get the next $MTEX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MTEX

Date	Price Target	Rating	Analyst

More analyst ratings

Mannatech Reports Financial Results for Second Quarter 2024
Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply
8/13/24 5:00:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care
Mannatech Announces Appointment of James Clavijo as Chief Financial Officer
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
7/1/24 5:46:00 PM ET
$AEZS
$MTEX
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products
Mannatech Reports Financial Results for First Quarter 2024
Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal
5/14/24 12:45:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care

Mannatech Reports Financial Results for Second Quarter 2024
Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply
8/13/24 5:00:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care
Mannatech Reports Financial Results for First Quarter 2024
Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal
5/14/24 12:45:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care
Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023
Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023. Fourth Quarter Highlights Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022. Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials. Operating loss in the fourth quarter was $0.9 million, improved from an operating loss
3/28/24 7:00:00 AM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care

Mannatech Announces Appointment of James Clavijo as Chief Financial Officer
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
7/1/24 5:46:00 PM ET
$AEZS
$MTEX
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products
Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO
Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr
3/13/24 7:30:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care
Mannatech Announces Results of Annual Shareholders' Meeting
Mannatech, Incorporated (NASDAQ:MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 6, 2023. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and David Johnson, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2022 and the first quarter of 2023. There were 1,872,422 outstanding shares of Mannatech's common stock as of April 20, 2023 entitled to vote and 1,270,511 shares, or approximately 67.9% represe
6/8/23 8:22:00 PM ET
$MTEX
Medicinal Chemicals and Botanical Products
Health Care

Mannatech Announces Promotion Of Landen Fredrick To President And CEO

Chat with this insight

Recent Analyst Ratings for
$MTEX

$MTEX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

$MTEX
SEC Filings

Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MTEX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Mannatech Incorporated

SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

$MTEX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Jobe Larry A sold $126,232 worth of Common Stock Par Value $0.0001 Per Share (16,288 units at $7.75), decreasing direct ownership by 23% to 54,721 units (SEC Form 4)

Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

Amendment: Director Fredrick J Stanley was granted 4,932 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 1% to 354,289 units (SEC Form 4)

$MTEX
Press Releases

Fastest customizable press release news feed in the world

$MTEX
Financials

Live finance-specific insights

$MTEX
Market Insights

Live Market Insights

$MTEX
Leadership Updates

Live Leadership Updates

Mannatech Reports Financial Results for Second Quarter 2024

Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

Mannatech Reports Financial Results for First Quarter 2024

Mannatech Reports Financial Results for Second Quarter 2024

Mannatech Reports Financial Results for First Quarter 2024

Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023

Mannatech Appoints James Clavijo As CFO, Effective July 1, 2024

Mannatech Q1 EPS $0.63 Up From $0.32 YoY, Sales $29.39M Down From $34.11M YoY

Mannatech Q4 EPS $(0.94) Up From $(3.78) YoY, Sales $32.69M Down From $34.34M YoY

Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

Mannatech Announces Results of Annual Shareholders' Meeting

Mannatech Announces Promotion Of Landen Fredrick To President And CEO

Chat with this insight

Recent Analyst Ratings for $MTEX

$MTEX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

$MTEX SEC Filings

Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

Mannatech Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MTEX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Mannatech Incorporated

SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

$MTEX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Jobe Larry A sold $126,232 worth of Common Stock Par Value $0.0001 Per Share (16,288 units at $7.75), decreasing direct ownership by 23% to 54,721 units (SEC Form 4)

Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

Amendment: Director Fredrick J Stanley was granted 4,932 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 1% to 354,289 units (SEC Form 4)

$MTEX Press Releases

Fastest customizable press release news feed in the world

$MTEX Financials

Live finance-specific insights

$MTEX Market Insights

Live Market Insights

$MTEX Leadership Updates

Live Leadership Updates

Mannatech Reports Financial Results for Second Quarter 2024

Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

Mannatech Reports Financial Results for First Quarter 2024

Mannatech Reports Financial Results for Second Quarter 2024

Mannatech Reports Financial Results for First Quarter 2024

Mannatech Reports Financial Results for Fourth Quarter and Full Year 2023

Mannatech Appoints James Clavijo As CFO, Effective July 1, 2024

Mannatech Q1 EPS $0.63 Up From $0.32 YoY, Sales $29.39M Down From $34.11M YoY

Mannatech Q4 EPS $(0.94) Up From $(3.78) YoY, Sales $32.69M Down From $34.34M YoY

Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

Mannatech Announces Results of Annual Shareholders' Meeting

Recent Analyst Ratings for
$MTEX

$MTEX
Insider Purchases

$MTEX
SEC Filings

$MTEX
Large Ownership Changes

$MTEX
Insider Trading

$MTEX
Press Releases

$MTEX
Financials

$MTEX
Market Insights

$MTEX
Leadership Updates